Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
2.270
-0.050 (-2.16%)
At close: Dec 20, 2024, 4:00 PM
2.230
-0.040 (-1.76%)
After-hours: Dec 20, 2024, 6:45 PM EST
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $9.09M in the quarter ending September 30, 2024, a decrease of -9.92%. This brings the company's revenue in the last twelve months to $36.79M, down -6.45% year-over-year. In the year 2023, Cumberland Pharmaceuticals had annual revenue of $39.55M, down -5.85%.
Revenue (ttm)
$36.79M
Revenue Growth
-6.45%
P/S Ratio
0.87
Revenue / Employee
$404,236
Employees
91
Market Cap
31.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 996.89M |
Nortech Systems | 135.57M |
Precision Optics Corporation | 18.98M |
BioAtla | 11.00M |
Moolec Science | 5.63M |
Envoy Medical | 278.00K |
CPIX News
- 11 days ago - Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga
- 12 days ago - FDA APPROVES ACETADOTE® sNDA - PRNewsWire
- 6 weeks ago - Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - PRNewsWire
- 6 weeks ago - CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - PRNewsWire
- 6 weeks ago - New Study Compares Caldolor® (ibuprofen injection) to ketorolac - PRNewsWire
- 7 weeks ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - PRNewsWire
- 4 months ago - Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript - Seeking Alpha